Rexahn Pharmaceuticals - Saving Lives through Innovation

Num	Subject	Type	Date	Click
98	Rexahn Pharmaceuticals to Present at the 12th Annual Bio CEO & Investor Conference		02/01/2010	377
....................................................................................................................................................................................................................................................................................................
97	Rexahn Pharmaceuticals Granted European Patent for Anti-cancer Compound RX-3117		01/19/2010	851
....................................................................................................................................................................................................................................................................................................
96	Rexahn and TheraTarget Form Nano Science Research Collaboration		12/14/2009	2341
....................................................................................................................................................................................................................................................................................................
95	Rexahn Pharmaceuticals Provides Third Quarter 2009 Business Update		11/17/2009	2080
....................................................................................................................................................................................................................................................................................................
94	Rexahn’s Archexin Recognized as One of Windhover’s Top 10 Most Promising Oncology Products		11/09/2009	1043
....................................................................................................................................................................................................................................................................................................
93	Rexahn Pharmaceuticals Announces Closing of Public Equity Offering		10/26/2009	1468
....................................................................................................................................................................................................................................................................................................
92	New Animal Study Featured in the Journal of Cellular Biochemistry Supports Rexahn's Archexin as Potent Inhibitor of Human Cancer Cell Growth		10/21/2009	812
....................................................................................................................................................................................................................................................................................................
91	Rexahn To Raise $5 Million in Registered Direct Offering		10/19/2009	485
....................................................................................................................................................................................................................................................................................................
90	Rexahn Reports Positive Top-line Phase IIa Data for Serdaxin in Patients with Major Depressive Disorder (MDD)		10/19/2009	982
....................................................................................................................................................................................................................................................................................................
89	Rexahn Pharmaceuticals to Present at the 8th Annual Bio Investor Forum on October 29, 2009		10/15/2009	789
....................................................................................................................................................................................................................................................................................................


[1] 2 3 4 5 6 7 8 9 10